Cargando…

HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI

BACKGROUND: Recent studies provide evidence that hepatocellular  adenomas  (HCAs) frequently take up gadoxetic acid (Gd-EOB) during the hepatobiliary phase (HBP). The purpose of our study was to investigate how to differentiate between Gd-EOB-enhancing HCAs and focal nodular hyperplasias (FNHs). We...

Descripción completa

Detalles Bibliográficos
Autores principales: Auer, Timo Alexander, Walter-Rittel, Thula, Geisel, Dominik, Schöning, Wenzel, Schmelzle, Moritz, Müller, Tobias, Sinn, Bruno, Denecke, Timm, Hamm, Bernd, Fehrenbach, Uli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885421/
https://www.ncbi.nlm.nih.gov/pubmed/33588783
http://dx.doi.org/10.1186/s12880-021-00552-0
_version_ 1783651602038521856
author Auer, Timo Alexander
Walter-Rittel, Thula
Geisel, Dominik
Schöning, Wenzel
Schmelzle, Moritz
Müller, Tobias
Sinn, Bruno
Denecke, Timm
Hamm, Bernd
Fehrenbach, Uli
author_facet Auer, Timo Alexander
Walter-Rittel, Thula
Geisel, Dominik
Schöning, Wenzel
Schmelzle, Moritz
Müller, Tobias
Sinn, Bruno
Denecke, Timm
Hamm, Bernd
Fehrenbach, Uli
author_sort Auer, Timo Alexander
collection PubMed
description BACKGROUND: Recent studies provide evidence that hepatocellular  adenomas  (HCAs) frequently take up gadoxetic acid (Gd-EOB) during the hepatobiliary phase (HBP). The purpose of our study was to investigate how to differentiate between Gd-EOB-enhancing HCAs and focal nodular hyperplasias (FNHs). We therefore retrospectively included 40 HCAs classified as HBP Gd-EOB-enhancing lesions from a sample of 100 histopathologically proven HCAs in 65 patients. These enhancing HCAs were matched retrospectively with 28 FNH lesions (standard of reference: surgical resection). Two readers (experienced abdominal radiologists blinded to clinical data) reviewed the images evaluating morphologic features and subjectively scoring Gd-EOB uptake (25–50%, 50–75% and 75–100%) for each lesion. Quantitative lesion-to-liver enhancement was measured in arterial, portal venous (PV), transitional and HBP. Additionally, multivariate regression analyses were performed. RESULTS: Subjective scoring of intralesional Gd-EOB uptake showed the highest discriminatory accuracies (AUC: 0.848 (R#1); 0.920 (R#2)—p < 0.001) with significantly higher uptake scores assigned to FNHs (Cut-off: 75%-100%). Typical lobulation and presence of a central scar in FNH achieved an accuracy of 0.750 or higher in at least one reader (lobulation—AUC: 0.809 (R#1); 0.736 (R#2); central scar—AUC: 0.595 (R#1); 0.784 (R#2)). The multivariate regression emphasized the discriminatory power of the Gd-EOB scoring (p = 0.001/OR:22.15 (R#1) and p < 0.001/OR:99.12 (R#2). The lesion-to-liver ratio differed significantly between FNH and HCA in the PV phase and HBP (PV: 132.9 (FNH) and 110.2 (HCA), p = 0.048 and HBP: 110.3 (FNH) and 39.2 (HCA), p < 0.001)), while the difference was not significant in arterial and transitional contrast phases (p > 0.05). CONCLUSION: Even in HBP-enhancing HCA, characterization of Gd-EOB uptake was found to provide the strongest discriminatory power in differentiating HCA from FNH. Furthermore, a lobulated appearance and a central scar are more frequently seen in FNH than in HCA.
format Online
Article
Text
id pubmed-7885421
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78854212021-02-17 HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI Auer, Timo Alexander Walter-Rittel, Thula Geisel, Dominik Schöning, Wenzel Schmelzle, Moritz Müller, Tobias Sinn, Bruno Denecke, Timm Hamm, Bernd Fehrenbach, Uli BMC Med Imaging Research Article BACKGROUND: Recent studies provide evidence that hepatocellular  adenomas  (HCAs) frequently take up gadoxetic acid (Gd-EOB) during the hepatobiliary phase (HBP). The purpose of our study was to investigate how to differentiate between Gd-EOB-enhancing HCAs and focal nodular hyperplasias (FNHs). We therefore retrospectively included 40 HCAs classified as HBP Gd-EOB-enhancing lesions from a sample of 100 histopathologically proven HCAs in 65 patients. These enhancing HCAs were matched retrospectively with 28 FNH lesions (standard of reference: surgical resection). Two readers (experienced abdominal radiologists blinded to clinical data) reviewed the images evaluating morphologic features and subjectively scoring Gd-EOB uptake (25–50%, 50–75% and 75–100%) for each lesion. Quantitative lesion-to-liver enhancement was measured in arterial, portal venous (PV), transitional and HBP. Additionally, multivariate regression analyses were performed. RESULTS: Subjective scoring of intralesional Gd-EOB uptake showed the highest discriminatory accuracies (AUC: 0.848 (R#1); 0.920 (R#2)—p < 0.001) with significantly higher uptake scores assigned to FNHs (Cut-off: 75%-100%). Typical lobulation and presence of a central scar in FNH achieved an accuracy of 0.750 or higher in at least one reader (lobulation—AUC: 0.809 (R#1); 0.736 (R#2); central scar—AUC: 0.595 (R#1); 0.784 (R#2)). The multivariate regression emphasized the discriminatory power of the Gd-EOB scoring (p = 0.001/OR:22.15 (R#1) and p < 0.001/OR:99.12 (R#2). The lesion-to-liver ratio differed significantly between FNH and HCA in the PV phase and HBP (PV: 132.9 (FNH) and 110.2 (HCA), p = 0.048 and HBP: 110.3 (FNH) and 39.2 (HCA), p < 0.001)), while the difference was not significant in arterial and transitional contrast phases (p > 0.05). CONCLUSION: Even in HBP-enhancing HCA, characterization of Gd-EOB uptake was found to provide the strongest discriminatory power in differentiating HCA from FNH. Furthermore, a lobulated appearance and a central scar are more frequently seen in FNH than in HCA. BioMed Central 2021-02-15 /pmc/articles/PMC7885421/ /pubmed/33588783 http://dx.doi.org/10.1186/s12880-021-00552-0 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Auer, Timo Alexander
Walter-Rittel, Thula
Geisel, Dominik
Schöning, Wenzel
Schmelzle, Moritz
Müller, Tobias
Sinn, Bruno
Denecke, Timm
Hamm, Bernd
Fehrenbach, Uli
HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
title HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
title_full HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
title_fullStr HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
title_full_unstemmed HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
title_short HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI
title_sort hbp-enhancing hepatocellular adenomas and how to discriminate them from fnh in gd-eob mri
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885421/
https://www.ncbi.nlm.nih.gov/pubmed/33588783
http://dx.doi.org/10.1186/s12880-021-00552-0
work_keys_str_mv AT auertimoalexander hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT walterrittelthula hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT geiseldominik hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT schoningwenzel hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT schmelzlemoritz hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT mullertobias hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT sinnbruno hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT denecketimm hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT hammbernd hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri
AT fehrenbachuli hbpenhancinghepatocellularadenomasandhowtodiscriminatethemfromfnhingdeobmri